Obesity drug tirzepatide approval in China strengthens market position amid GLP-1 agonist…
Benemae’s benaglutide injection (Feisumei) was the first innovator approved for obesity in July 2023 in China followed by Novo…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
tirzepatide
Viking Therapeutics’ obesity drug could become direct competitor to Eli Lilly’s tirzepatide:…
With promising Phase IIa results and a dual GLP-1/GIP receptor mechanism, VK2735 could soon compete directly with tirzepatide in…
Eli Lilly’s Mounjaro to become leading GLP-1 therapy for type 2 diabetes in NHS in UK: GlobalData
The National Institute for Health and Care Excellence (NICE) provided guidance in August 2023 explaining that where triple therapy…